IL1B and adult-onset Still disease: While several studies show the efficacy of anti-TNF agents (infliximab, etanercept, and adalimumab) in refractory AOSD [40–43], IL-1 inhibition is considered the mainstay of treatment for refractory AOSD leading to significant improvement in both clinical and laboratory terms [44, 45].